S&P Futures
4,145.25 +14.75 (+0.36%) Dow Futures
34,112.00 +117.00 (+0.34%) Nasdaq Futures
12,602.50 +57.25 (+0.46%) Russell 2000 Futures
1,958.10 +8.20 (+0.42%) Crude Oil
78.44 -0.03 (-0.04%) Gold
1,890.50 -0.20 (-0.01%)
Selecta Biosciences, Inc. (SELB)
After hours:
- GlobeNewswire
Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023. SVB Securities Global Biopharma
- Benzinga
Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ: SELB) from $9 to $10 while maintaining the Buy rating ahead of the upcoming data from two Phase 3 studies of SEL-212 for chronic refractory gout. The analyst expects positive top-line data in 1Q23 for SEL-212. While many will likely compare the results to Horizon Therapeutics PLC's (NASDAQ: HZNP) Krystexxa and the various immunomodulating combinations, Canaccord sees SEL-212 as a step ahead in the gout treatmen
- Simply Wall St.
Positive week for Selecta Biosciences, Inc. (NASDAQ:SELB) institutional investors who lost 34% over the past year
Every investor in Selecta Biosciences, Inc. ( NASDAQ:SELB ) should be aware of the most powerful shareholder groups...
